Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, LS9 7TF, UK.
MD Anderson Cancer Centre, Houston, Texas, TX 77030, USA.
Sci Rep. 2017 Mar 28;7:45293. doi: 10.1038/srep45293.
Male breast cancer (MBC) is rare. We assembled 446 MBCs on tissue microarrays and assessed clinicopathological information, together with data from 15 published studies, totalling 1984 cases. By immunohistochemistry we investigated 14 biomarkers (ERα, ERβ1, ERβ2, ERβ5, PR, AR, Bcl-2, HER2, p53, E-cadherin, Ki67, survivin, prolactin, FOXA1) for survival impact. The main histological subtype in our cohort and combined analyses was ductal (81%, 83%), grade 2; (40%, 44%), respectively. Cases were predominantly ERα (84%, 82%) and PR positive (74%, 71%), respectively, with HER2 expression being infrequent (2%, 10%), respectively. In our cohort, advanced age (>67) was the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, respectively). Node positivity negatively impacted DFS (p = 0.04). FOXA1 p = 0.005) and AR p = 0.009) were both positively prognostic for DFS, remaining upon multivariate analysis. Network analysis showed ERα, AR and FOXA1 significantly correlated. In summary, the principle phenotype of MBC was luminal A, ductal, grade 2. In ERα+ MBC, only AR had prognostic significance, suggesting AR blockade could be employed therapeutically.
男性乳腺癌(MBC)较为罕见。我们在组织微阵列上收集了 446 例 MBC,并评估了临床病理信息,同时结合了来自 15 项已发表研究的数据,共计 1984 例。通过免疫组织化学,我们研究了 14 种生物标志物(ERα、ERβ1、ERβ2、ERβ5、PR、AR、Bcl-2、HER2、p53、E-钙黏蛋白、Ki67、存活素、催乳素、FOXA1)对生存的影响。在我们的队列和联合分析中,主要的组织学亚型是导管(81%,83%),分别为 2 级;(40%,44%)。病例主要为 ERα(84%,82%)和 PR 阳性(74%,71%),HER2 表达均不常见(分别为 2%,10%)。在我们的队列中,年龄较大(>67 岁)是总生存(OS)和无病生存(DFS)的最强预测因素(p = 0.00001;p = 0.01,分别)。淋巴结阳性对 DFS 有负面影响(p = 0.04)。FOXA1 p = 0.005)和 AR p = 0.009)对 DFS 均具有预后意义,在多变量分析中仍然如此。网络分析表明 ERα、AR 和 FOXA1 具有显著相关性。总之,MBC 的主要表型为 ERα+腔 A、导管、2 级。在 ERα+MBC 中,只有 AR 具有预后意义,提示 AR 阻断可能具有治疗作用。